Sponsored by
As I understand it, the failure was that the median progression free survival did not improve by adding Opdivo to the standard chemoradiation. This is not surprising as most of the immunotherapies seem to work really well on a small subset of the population. We see this in a long tail of survivors. However, even when there is an impressive improvement in long term survival in less than 50% of the patients, the median survival would not be expected to change much. This data has to be looked at closely to try to identify patients who were helped, and then try it in that subset of patient, perhaps in combination with other immunotherapies.